Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1,9 CHF | +9,07 % | -3,55 % | -10,12 % |
Resumen de negocios
Número de empleados: 650
Ventas por actividad
CHF en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Drugs
100,0
%
| 35 | 100,0 % | 97 | 100,0 % | +174,70 % |
Ventas por región
CHF en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Switzerland
48,0
%
| 35 | 100,0 % | 47 | 48,0 % | +31,77 % |
Japan
45,3
%
| - | - | 44 | 45,3 % | - |
United States
5,7
%
| - | - | 6 | 5,7 % | - |
Rest of World
1,0
%
| 0 | 0,0 % | 1 | 1,0 % | - |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 01/06/17 |
André Muller
DFI | Director of Finance/CFO | 60 | 01/06/17 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 01/06/17 |
Andrew C. Weiss
IRC | Investor Relations Contact | 55 | 01/06/17 |
Alberto Gimona
PRN | Corporate Officer/Principal | 64 | 01/02/19 |
Julien Gander
LAW | General Counsel | 45 | - |
Human Resources Officer | 45 | 01/06/17 | |
Simon Jose
PRN | Corporate Officer/Principal | 58 | 01/12/18 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 13/05/20 |
Peter Kellogg
BRD | Director/Board Member | 67 | 12/05/21 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 01/06/17 |
Felix R. Ehrat
BRD | Director/Board Member | 67 | 13/05/20 |
Sandy Mahatme
BRD | Director/Board Member | 59 | 13/05/20 |
Mathieu Simon
CHM | Chairman | 67 | 03/05/19 |
Srishti Gupta
BRD | Director/Board Member | 47 | 12/05/21 |
Director/Board Member | 61 | 04/05/23 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 188 844 867 | 110 902 769 ( 58,73 %) | 9 653 500 ( 5,112 %) | 58,73 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
IDORSIA LTD 4.80% | 9 049 500 | 4.80% | 28 413 439 $ |
1 301 128 | 10.31% | 14 113 492 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. |
Pharmaceuticals: Major
|
Sector
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-10,12 % | 341 M | |
-2,13 % | 103 mil M | |
+0,67 % | 95,71 mil M | |
+1,69 % | 22,02 mil M | |
-16,97 % | 20,9 mil M | |
-9,30 % | 17,85 mil M | |
-41,01 % | 16,21 mil M | |
-14,74 % | 15,52 mil M | |
+3,32 % | 13,86 mil M | |
+34,26 % | 12,04 mil M |
- Bolsa de valores
- Acciones
- Acción IDIA
- Empresa Idorsia Ltd